Santica Introduces New Cellulite Reducing Pill
Eddie Catalfamo, president and CEO of Santica Research Labs, said: “This unique supplement, made from carefully selected natural botanical extracts, targets the underlying factors that contribute to the
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.